SEC Comment Letter 0000000000-23-004148 to IOVANCE BIOTHERAPEUTICS, INC. (IOVA) (CIK 0001425205) (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) (CIK 0001425205)
Date: April 25, 2023 · CIK: 0001425205 · Accession: 0000000000-23-004148
AI Filing Summary & Sentiment
File numbers found in text: 001-36860
Letter
United States securities and exchange commission logo April 25, 2023 Frederick Vogt, Ph.D, J.D. Interim Chief Executive Officer and President, General Counsel IOVANCE BIOTHERAPEUTICS, INC. 825 Industrial Road, Suite 400 Can Carlos, CA 94070 Re:IOVANCE BIOTHERAPEUTICS, INC. Preliminary Revised Schedule 14A Filed April 19, 2023 File No. 001-36860 Dear Frederick Vogt: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
April 25, 2023
Frederick Vogt, Ph.D, J.D.
Interim Chief Executive Officer and President, General Counsel
IOVANCE BIOTHERAPEUTICS, INC.
825 Industrial Road, Suite 400
Can Carlos, CA 94070
Re:IOVANCE BIOTHERAPEUTICS, INC.
Preliminary Revised Schedule 14A
Filed April 19, 2023
File No. 001-36860
Dear Frederick Vogt:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences